TTP Launches New PoC Diagnostic Instrument Development Service
News Aug 04, 2016
The Technology Partnership announced the launch of Desktop Biology™. The new service will enable point-of-care diagnostic providers to rapidly convert their biological assay into a market-ready system capable of producing a result in as little as 15 minutes.
The new service provides an accessible and rapid route to market, offering a seamless approach for companies looking to accelerate the development of their assay to a product for use in diagnostics or research. Made possible with TTP’s expertise in regulated environments and fast track system development, this advance will enable rapid translation of a customer’s biology to a product on the market. Key to this service is the ability for TTP’s team to understand the fundamental steps required to convert lab-based biological processes (for example, sample preparation, labelling and assay measurement) to a functional low-cost disposable and small instrument.
Users of the Desktop Biology service will have the opportunity to benefit from TTP’s in-house platforms and technologies, that have been designed to translate complex biological assays into low-cost, disposable consumables. For example, one platform enables open-access biology and liquid handling for 30 µL to 2 mL volumes, while another is purpose-built for dealing with complex processes such as small liquid volumes in the range of 10 µL to 200 µL whilst maintaining a low disposable cost.
Desktop Biology customers will also have access to TTP’s novel IP that has been especially developed to address some of the key challenges in the biological arena. This includes technologies that provide benefits for a number of assay steps, including biological and cellular deposition, methods for the rapid lysing of high sample volumes, high speed thermocycling, optical and electronic detection systems, and unique low profile and non- pulsatile pumps for highly controlled liquid movement.
“In recent years, we’ve seen an increased interest in translating processes and instrumentation from the central lab to the researcher’s or clinic’s desktop”, said Dr Giles Sanders, at TTP. “We’re confident that this service and related TTP platforms will prove attractive to assay and instrument providers in this emerging market, by providing an accelerated route to manufacture that is augmented by our expertise in product development, engineering and the underlying biology of assay design and development.”
Scientists have identified sodium glucose transporter 2 (SGLT2) as a mechanism that lung cancer cells can utilize to obtain glucose, which is key to their survival and promotes tumor growth. The finding provides evidence that SGLT2 may be a novel biomarker that scientists can use to help diagnose precancerous lung lesions and early-stage lung cancers.READ MORE